Regeneron Pharmaceuticals (REGN) Stock Price
Regeneron Pharmaceuticals Price
Over the last 19 years Regeneron Pharmaceuticals grew revenue by 33.0% annually, reaching 14.34 B USD. Earnings per share have grown at 15.6% per year over the last 13 years. For Regeneron Pharmaceuticals, the net margin of 31.4% is down versus 50.2% a few years ago. At today's price the dividend yield works out to roughly 0.45%. The payout ratio is around 8% of earnings. The consensus 12-month price target for Regeneron Pharmaceuticals is 800.00 USD, about 2.9% above where the stock trades today. Of 38 analysts, 26 rate the stock a buy — an overall Buy consensus. The stock trades about 40% above its 52-week low.
Regeneron Pharmaceuticals stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Regeneron Pharmaceuticals over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Regeneron Pharmaceuticals stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Regeneron Pharmaceuticals's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Regeneron Pharmaceuticals Price |
|---|---|
| 9/15/2026 | 777.18 USD |
| 9/14/2026 | 791.42 USD |
| 9/11/2026 | 782.97 USD |
| 9/10/2026 | 794.40 USD |
| 9/9/2026 | 807.65 USD |
| 9/8/2026 | 811.18 USD |
| 9/4/2026 | 834.64 USD |
| 9/3/2026 | 843.47 USD |
| 9/2/2026 | 852.03 USD |
| 9/1/2026 | 823.82 USD |
| 8/31/2026 | 796.34 USD |
| 8/28/2026 | 793.51 USD |
| 8/27/2026 | 813.91 USD |
| 8/26/2026 | 814.79 USD |
| 8/25/2026 | 833.56 USD |
| 8/24/2026 | 825.53 USD |
| 8/21/2026 | 834.04 USD |
| 8/20/2026 | 826.64 USD |
| 8/19/2026 | 834.50 USD |
| 8/18/2026 | 816.84 USD |
| 8/14/2026 | 803.48 USD |
| 8/13/2026 | 805.97 USD |
| 8/12/2026 | 797.99 USD |
| 8/11/2026 | 797.00 USD |
| 8/10/2026 | 801.78 USD |
| 8/7/2026 | 784.36 USD |
| 8/6/2026 | 772.11 USD |
| 8/5/2026 | 768.89 USD |
| 8/4/2026 | 757.49 USD |
| 8/3/2026 | 759.24 USD |
Regeneron Pharmaceuticals Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Regeneron Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| DIVIDEND GROWTHDIV. GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.10 | 4.86 | 5.87 | 6.71 | 7.86 | 8.50 | 16.07 | 12.17 | 13.12 | 14.20 | 14.34 | 17.06 | 18.60 | 19.87 | 21.34 | 22.41 |
| 45.55 | 18.45 | 20.82 | 14.27 | 17.18 | 8.06 | 89.14 | -24.26 | 7.76 | 8.27 | 0.99 | 18.93 | 9.06 | 6.80 | 7.40 | 5.01 |
| 90.45 | 93.83 | 93.24 | 93.53 | 90.05 | 84.04 | 83.06 | 85.99 | 93.26 | 86.12 | 85.36 | 85.36 | 85.36 | 85.36 | 85.36 | 85.36 |
| 3.71 | 4.56 | 5.48 | 6.28 | 7.08 | 7.14 | 13.35 | 10.47 | 12.23 | 12.23 | 12.24 | 14.56 | 15.88 | 16.96 | 18.21 | 19.13 |
| 1.25 | 1.33 | 2.08 | 2.53 | 2.21 | 3.63 | 9.00 | 5.39 | 4.05 | 3.99 | 3.58 | 6.59 | 7.42 | 8.22 | 9.22 | 9.75 |
| 30.49 | 27.37 | 35.41 | 37.76 | 28.09 | 42.76 | 56.03 | 44.24 | 30.85 | 28.09 | 24.94 | 38.61 | 39.88 | 41.36 | 43.19 | 43.50 |
| 0.64 | 0.90 | 1.20 | 2.44 | 2.12 | 3.51 | 8.08 | 4.34 | 3.95 | 4.41 | 4.50 | 5.76 | 6.47 | 7.23 | 8.00 | 8.46 |
| 82.76 | 40.72 | 33.85 | 104.01 | -13.46 | 66.10 | 129.86 | -46.28 | -8.88 | 11.61 | 2.09 | 27.93 | 12.36 | 11.74 | 10.55 | 5.79 |
| – | – | – | – | – | – | – | – | – | – | 3.52 | 3.76 | 3.76 | 3.76 | – | – |
| – | – | – | – | – | – | – | – | – | – | – | 6.82 | – | – | – | – |
| 115.66 | 115.79 | 116.20 | 114.80 | 114.32 | 112.21 | 113.20 | 114.00 | 113.80 | 113.80 | 107.50 | 107.50 | 107.50 | 107.50 | 107.50 | 107.50 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Regeneron Pharmaceuticals generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Regeneron Pharmaceuticals retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Regeneron Pharmaceuticals's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Regeneron Pharmaceuticals has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Regeneron Pharmaceuticals's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Regeneron Pharmaceuticals stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Regeneron Pharmaceuticals Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Regeneron Pharmaceuticals business model & stock analysis
Regeneron Pharmaceuticals SWOT Analysis
Strengths
Regeneron Pharmaceuticals Inc has several strengths that contribute to its success in the market. These strengths include:
- Strong Research and Development: Regeneron has a robust research and development pipeline, allowing for the development of innovative pharmaceutical products.
- Diverse Product Portfolio: The company offers a wide range of drugs targeting various therapeutic areas, reducing its reliance on a single product.
- Partnerships and Collaborations: Regeneron has established strategic partnerships with other pharmaceutical companies, enabling access to new technologies and markets.
- Strong Financial Performance: The company has consistently demonstrated strong financial performance, with steady revenue growth and profitability.
Weaknesses
Despite its strengths, Regeneron Pharmaceuticals Inc also has certain weaknesses that need to be addressed. These weaknesses include:
- Heavy Dependence on Key Products: The company relies heavily on a few key products for a significant portion of its revenue, making it vulnerable to market fluctuations and patent expirations.
- Regulatory Risks: As a pharmaceutical company, Regeneron is subject to strict regulatory approvals and potential delays, which can impact product launches and timelines.
- High Research and Development Costs: Developing innovative drugs involves substantial investment, making it essential for the company to maintain a steady stream of successful product launches.
Opportunities
Regeneron Pharmaceuticals Inc can capitalize on several opportunities to further enhance its market position. These opportunities include:
- Expanding Global Markets: The pharmaceutical industry offers significant growth opportunities in emerging markets, enabling the company to tap into new patient populations and revenue streams.
- Increasing Demand for Biologics: The growing demand for biologic drugs presents an opportunity for Regeneron, given its expertise in developing and manufacturing biologic pharmaceuticals.
- Research Collaboration: Collaborating with academic institutions and research organizations can lead to breakthrough discoveries and potential partnerships for innovative drug development.
Threats
Regeneron Pharmaceuticals Inc also faces certain threats that could impact its business and growth prospects. These threats include:
- Intense Competition: The pharmaceutical industry is highly competitive, with the presence of numerous prominent players. This poses a threat to the company's market share and pricing power.
- Pricing and Reimbursement Pressures: Efforts to control healthcare costs and reimbursement policies can impact the pricing and profitability of pharmaceutical products.
- Intellectual Property Challenges: Regeneron faces the risk of patent expirations and potential legal challenges from generic drug manufacturers, which can lead to a loss of market exclusivity.
Regeneron Pharmaceuticals Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Regeneron Pharmaceuticals Segments
Regeneron Pharmaceuticals Revenue by Segment (1/8)
3 Years
5 Years
Max
Details
Regeneron Pharmaceuticals Revenue by Segment (2/8)
3 Years
5 Years
Max
Details
Regeneron Pharmaceuticals Revenue by Segment (3/8)
3 Years
5 Years
Max
Details
Regeneron Pharmaceuticals Revenue by Segment (4/8)
3 Years
5 Years
Max
Details
Regeneron Pharmaceuticals Revenue by Segment (5/8)
3 Years
Max
Details
Regeneron Pharmaceuticals Revenue by Segment (6/8)
3 Years
5 Years
Max
Details
Regeneron Pharmaceuticals Revenue by Segment (7/8)
3 Years
5 Years
Max
Details
Regeneron Pharmaceuticals Revenue by Segment (8/8)
Max
Details
Regeneron Pharmaceuticals Revenue by Region
3 Years
Max
Details
Regeneron Pharmaceuticals Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Regeneron Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio
Regeneron Pharmaceuticals annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Regeneron Pharmaceuticals's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Regeneron Pharmaceuticals's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Regeneron Pharmaceuticals's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Regeneron Pharmaceuticals shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Regeneron Pharmaceuticals Dividend History
2 years of dividend payments
Regeneron Pharmaceuticals dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Regeneron Pharmaceuticals dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Regeneron Pharmaceuticals forecasts and price targets in September 2026
Analyst Price Targets 2026Regeneron Pharmaceuticals Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/17/2026 | Maintained | Market Perform | – | |
| 8/3/2026 | Maintained | Buy | 39 | |
| 8/3/2026 | Maintained | Neutral | 46 | |
| 7/31/2026 | Maintained | Equal Weight | 58 | |
| 7/31/2026 | Maintained | Buy | – | |
| 7/31/2026 | Maintained | Sector Perform | 48 | |
| 7/31/2026 | Maintained | Equal Weight | 46 | |
| 7/31/2026 | Maintained | Overweight | 38 | |
| 7/21/2026 | Maintained | Buy | 39 | |
| 7/9/2026 | Maintained | Overweight | 54 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Regeneron Pharmaceuticals Earnings Calls
Regeneron Pharmaceuticals Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 7/30/2026 | 10.73USD | - | 3.90 BUSD | - | 2026 Q2 |
| 4/29/2026 | 9.32USD | - | 3.54 BUSD | - | 2026 Q1 |
| 1/30/2026 | 10.84USD | - | 3.87 BUSD | - | 2025 Q4 |
| 5/2/2024 | 10.45USD | - | 3.29 BUSD | - | 2024 Q1 |
| 2/1/2024 | 10.89USD | - | 3.32 BUSD | - | 2023 Q4 |
| 8/1/2023 | 11.22USD | - | 3.10 BUSD | - | 2023 Q2 |
| 5/2/2023 | 10.63USD | - | 3.01 BUSD | - | 2023 Q1 |
| 2/2/2023 | 10.87USD | - | 3.27 BUSD | - | 2022 Q4 |
| 11/3/2022 | 9.67USD | 11.14USD | 2.91 BUSD | - | 2022 Q3 |
| 8/3/2022 | 9.02USD | 9.77USD | 2.84 BUSD | - | 2022 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Regeneron Pharmaceuticals stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Regeneron Pharmaceuticals shareholder structure
| % | Name |
|---|---|
8.46362% | |
6.29485% | |
4.41211% | |
4.21702% | |
4.07851% | |
2.57479% |
Regeneron Pharmaceuticals Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
12.14% | SEC ↗ | |
11.00% | SEC ↗ | |
10.40% | SEC ↗ | |
9.10% | SEC ↗ | |
8.30% | SEC ↗ | |
8.10% | SEC ↗ | |
7.72% | SEC ↗ | |
7.37% | SEC ↗ | |
7.30% | SEC ↗ | |
6.71% | SEC ↗ |
Regeneron Pharmaceuticals Executives and Management Board
19 members · avg. age 67 · 26 % women
Mr. Daniel Van Plew (52)
Executive Vice President, General Manager - Industrial Operations and Product Supply
8.66 M USD
Management
Dr. Andrew Murphy (67)
Executive Vice President - Research
Mr. Joseph LaRosa (66)
Executive Vice President, General Counsel, Secretary
Ms. Marion McCourt (65)
Executive Vice President - Commercial
Dr. Leonard Schleifer (72)
Co-Chairman of the Board, President, Chief Executive Officer, Founder · since 1988
Dr. George Yancopoulos (65)
Co-Chairman of the Board, President, Chief Scientific Officer
Mr. Christopher Fenimore (54)
Chief Financial Officer, Executive Vice President - Finance
Board of Directors
Ms. Christine Poon (72)
Lead Independent Director
Dr. Michael Brown (84)
Independent Director
Mr. George Sing (75)
Independent Director
Mr. Arthur Ryan (82)
Independent Director
Dr. Huda Zoghbi (70)
Independent Director
Dr. Bonnie Bassler (62)
Independent Director
Regeneron Pharmaceuticals Supply Chain
Regeneron Pharmaceuticals Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.56 | 0.60 | 0.75 | ||
| 2 | 0.60 | 0.50 | 0.68 | ||
| 3 | 0.65 | 0.67 | 0.53 | ||
| 4 | 0.67 | 0.67 | 0.52 | ||
| 5 | -0.32 | 0.23 | 0.47 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | Mitsubishi Chemical Holdings Corporation | 0.22 | — | — | |
| 2 | Sanofi | 0.50 | 0.24 | — | |
| 3 | Roche Holding AG | 0.25 | 0.46 | — | |
| 4 | Novartis AG | 0.23 | -0.33 | — | |
| 5 | Decibel Therapeutics | -0.46 | -0.60 | — |
Frequently asked questions about Regeneron Pharmaceuticals
The business model of Regeneron Pharmaceuticals Inc. revolves around the research, development, and commercialization of innovative biopharmaceutical products. Regeneron focuses on discovering, designing, and manufacturing novel medicines that address unmet medical needs. The company employs advanced technologies, including monoclonal antibody platforms and genetically modified mice, to develop therapies across various therapeutic areas, such as ophthalmology, oncology, and inflammatory diseases. By continuously investing in research and strategic collaborations, Regeneron strives to deliver life-changing treatments, improve patient outcomes, and become a leading force in the biopharmaceutical industry. Visit our website for more information about Regeneron Pharmaceuticals Inc. and its business model.
Regeneron Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.
The main competitors of Regeneron Pharmaceuticals Inc in the market include major pharmaceutical companies like Roche Holding AG, Amgen Inc, and Pfizer Inc. These companies are also involved in the development and commercialization of biopharmaceutical products, competing within the same therapeutic areas as Regeneron.
Regeneron Pharmaceuticals Inc, founded in 1988, is a renowned American biotechnology company specializing in the discovery, development, and commercialization of innovative medicines. Headquartered in Tarrytown, New York, Regeneron has a rich history of pioneering scientific breakthroughs. The company's success can be attributed to its robust research and development initiatives, focusing on various therapeutic areas such as oncology, ophthalmology, cardiovascular diseases, and rare genetic disorders. Regeneron's remarkable achievements include the development of EYLEA® (a leading treatment for retinal diseases) and the groundbreaking antibody cocktail, REGN-COV2, used for COVID-19 treatment. Renowned for its dedication to rigorous scientific research, Regeneron Pharmaceuticals Inc has established itself as a leader in the biopharmaceutical industry.
Regeneron Pharmaceuticals Inc. has achieved several significant milestones since its inception. Notably, the company received FDA approval for its groundbreaking drug, EYLEA®, in 2011, which revolutionized the treatment of age-related macular degeneration. Regeneron also gained recognition for the development of its therapy, Dupixent®, for atopic dermatitis, asthma, and other allergic conditions. In addition, the company has made significant advancements in the field of immuno-oncology with its innovative drug, Libtayo®, approved for the treatment of certain types of skin and lung cancers. Regeneron continues to drive progress in the biopharmaceutical industry by focusing on novel research and development initiatives.
Regeneron Pharmaceuticals Inc primarily operates in various countries and regions around the world. The company has a global presence with key markets in the United States, Europe, and other international locations. Through its strong partnerships and collaborations, Regeneron has expanded its reach and established a significant presence in the biopharmaceutical industry. With its dedication to scientific innovation and breakthrough treatments, Regeneron Pharmaceuticals Inc continues to make a meaningful impact on patients' lives worldwide.
Regeneron Pharmaceuticals Inc is a leading biotechnology company that values innovation, integrity, and collaboration. With a corporate philosophy centered around science-driven discoveries and patient-focused solutions, Regeneron aims to improve lives through its research and development of therapeutic products. They prioritize the use of cutting-edge technologies to address unmet medical needs and strive to deliver impactful medicines to patients worldwide. Regeneron's commitment to transparency, ethical practices, and scientific excellence has established its reputation as a trusted and reliable healthcare partner.
Analysts currently set an average price target of 820.65 USD for the Regeneron Pharmaceuticals stock (median: 800.00 USD), implying +5.6 % versus the latest price. The consensus is based on 38 analyst ratings.
38 analysts currently rate the Regeneron Pharmaceuticals stock: 26 recommend buying, 12 holding and 0 selling. For 2026, analysts expect Regeneron Pharmaceuticals to generate revenue of 17.06 B USD and earnings per share of 53.61 USD.
Converted at the current exchange rate, the Regeneron Pharmaceuticals share trades at 672.79 EUR (777.18 USD).
The Regeneron Pharmaceuticals share (REGN) is listed on 11 stock exchanges, including: NASDAQ (REGN), London (0R2M.L), SIX (Zürich) (RGO.SW), XETRA (RGO.DE), Frankfurt (RGO.F), München (RGO.MU), Düsseldorf (RGO.DU), Hamburg (RGO.HM).
Regeneron Pharmaceuticals is a biotechnology company based in the United States that focuses on researching, developing, and marketing medications. It was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into various business divisions that address different medical conditions. This includes the field of ophthalmology, where Regeneron has developed the medication Eylea®, an effective treatment for age-related macular degeneration and other eye diseases. The sales in this area amounted to approximately $7.7 billion in 2020. Another important area is oncology, where Regeneron has developed the cancer medication Libtayo®, which is used to treat skin cancer and lung cancer. The sales in this area amounted to approximately $340 million in 2020. Regeneron is also involved in inflammation diseases, genetic diseases, and infectious diseases. The company has several promising medications in development in these areas, including a treatment for COVID-19. Regeneron collaborates closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with whom Regeneron has already brought several successful medications to the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, the R&D expenditure amounted to approximately $3.7 billion, which is about 40 percent of the total revenue. The company employs a large number of scientists and researchers who are constantly working on new medications. Regeneron also values the promotion of young talent. The company has established an extensive scholarship program specifically targeted at students and young scientists. This ensures that highly qualified professionals will be available in the future to further advance the company. In summary, Regeneron's business model specializes in research and development of new medications. The company works closely with various partners and has already brought several promising medications to the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers. Regeneron Pharmaceuticals is a US biotechnology company that specializes in the research, development, and marketing of medications. The company was founded in 1988 by Leonard Schleifer and George Yancopoulos and is headquartered in Tarrytown, New York. Regeneron is divided into several business areas that deal with different medical conditions. This includes the field of ophthalmology, in which Regeneron has developed the effective drug Eylea® for age-related macular degeneration and other eye diseases. Sales in this area were around $7.7 billion in 2020. Another important area is oncology, in which Regeneron has developed the cancer drug Libtayo®, which is used to treat skin cancer and lung cancer. Sales in this area were around $340 million in 2020. Other business areas of Regeneron include inflammatory diseases, genetic diseases, and infectious diseases. In these areas, the company has already developed several promising drugs, including a treatment for COVID-19. Regeneron works closely with various partners in the pharmaceutical and biotech industry. This includes the British pharmaceutical company Sanofi, with which Regeneron has already successfully launched several drugs on the market. The company also has partnerships with other major industry players such as Bayer and Roche. Regeneron places great emphasis on research and development and invests a significant amount of money in this area. In 2020, R&D spending was around $3.7 billion, approximately 40 percent of total revenue. The company employs a large number of scientists and researchers who are constantly working on new drugs. Regeneron also places great importance on promoting young talent. The company has launched an extensive scholarship program specifically targeting students and young scientists. This is to ensure that highly qualified professionals are available in the future to further advance the company. In conclusion, Regeneron's business model specializes in the research and development of new medications. The company works closely with various partners and has already launched several promising drugs on the market. Regeneron places great importance on promoting young talent and building a highly qualified team of scientists and researchers.
The expected revenue of Regeneron Pharmaceuticals is 17.06 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Regeneron Pharmaceuticals is 5.76 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Regeneron Pharmaceuticals is currently 14.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Regeneron Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Regeneron Pharmaceuticals is currently 4.90. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Regeneron Pharmaceuticals stock.
The Eulerpool Quality Score for Regeneron Pharmaceuticals is 6/10.
The ISIN of Regeneron Pharmaceuticals is US75886F1075. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Regeneron Pharmaceuticals is 881535. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Regeneron Pharmaceuticals is REGN. The ticker symbol is used to trade Regeneron Pharmaceuticals shares on the stock exchange.
Over the past 12 months, Regeneron Pharmaceuticals paid a dividend of 3.52 USD . This corresponds to a dividend yield of about 0.45 %. For the coming 12 months, Regeneron Pharmaceuticals is expected to pay a dividend of 3.76 USD.
The current dividend yield of Regeneron Pharmaceuticals is 0.45 %.
Regeneron Pharmaceuticals pays a dividend, distributed in the months of November, February, May, August.
Regeneron Pharmaceuticals paid dividends every year for the past 1 years.
For the upcoming 12 months, dividends amounting to 3.76 USD are expected. This corresponds to a dividend yield of 0.48 %.
Regeneron Pharmaceuticals is assigned to the 'Health' sector.
To receive the latest dividend of Regeneron Pharmaceuticals from 8/31/2026 amounting to 0.94 USD, you needed to have the stock in your portfolio before the ex-date on 8/18/2026.
The last dividend was paid out on 8/31/2026.
In the year 2025, Regeneron Pharmaceuticals distributed 3.52 USD as dividends.
The dividends of Regeneron Pharmaceuticals are distributed in USD.
Regeneron Pharmaceuticals stock
Regeneron Pharmaceuticals Peer Group
Regeneron Pharmaceuticals Ticker
Regeneron Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Regeneron Pharmaceuticals
Our stock analysis for Regeneron Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regeneron Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.